**Suppl 2.** Summary of Findings: Effect on Lesion Size

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Intervention vs. Comparator** | **Studies (design, population/species)** | **Mean difference in lesion volume (cm3)** | **Certainty (GRADE)** | **Downgrade reasons (GRADE)** |
| Relugolix 40 mg/day (24 wk) vs. Leuprorelin (3.75/1.88 mg q4wk) | 1 RCT (Japanese women with endometriosis) | Relugolix: -12.26 ± 17.52 cm3; Leuprorelin: -14.10 ± 18.81 cm3; MD ≈ -1.84 cm3 (slightly smaller reduction with Relugolix) | Moderate | Downgraded 1 level for imprecision (wide confidence interval; small mean difference) |
| Linzagolix 50 mg/kg (oral, rat model) vs. Vehicle (control) | 1 study (rats with induced endometriosis) | Significant reduction in cyst volume vs control at ≥ 50 mg/kg; MD not reported (exact volumes not given) | Very Low | Downgraded 2 levels for indirectness (animal data) and imprecision (small sample size) |